gation disclosed an ankle pressure index of 0 7, indicative of peripheral vascular disease. This index is a ratio of the systolic pressure of the posterior tibial artery at the ankle to that of the brachial artery and is normally greater than 1-0. There was no history of any skin disorder. Results of investigations were: haemoglobin concentration 11-6 g/dl, normochromic normocytic pattern; erythrocyte sedimentation rate 83 mm in the first hour; blood glucose concentration 14-3 mmol/l (257-4 mg/100 ml); and normal urea and electrolyte values. He was started on glibenclamide 5 mg daily and referred for surgical treatment.
The great toe was amputated but, unfortunately, this failed to heal and he had a below knee amputation three weeks later. He made a good postoperative recovery and underwent early rehabilitation with a prosthesis, which is the policy for diabetic amputees. He continued with glibenclamide and was given no other medication. Two months postoperatively and after several weeks of active rehabilitation he developed a blistering eruption over the amputated stump (figure). These clear, tense blisters developed on normal skin. Biopsy ...
Appearances of stump (below knee) two months after amputation.
showed a large subepidermal blister with a strong inflammatory component including numerous eosinophils. Direct immunofluorescence showed deposition of IgG along the basement membrane extending into the roof of the blister. These are the findings of bullous pemphigoid, but circulating antibasement membrane antibody was not detected on two separate occasions. The patient responded to rest and topical steroid treatment with clobetasol propionate ointment, and mobilisation was recommended. This caused a recurrence of the blistering eruption, remaining localised to the amputated stump, and final control was achieved only with oral prednisolone 15 mg daily. At no time did the eruption become generalised.
Comment
There are many skin problems which can affect the amputee who wears a prosthesis. The skin is exposed to frictional trauma and the tightly fitting socket of the prosthesis prevents air circulating, trapping perspiration. These factors increase the likelihood of skin complications, and contact dermatitis, eczemas, epidermoid cysts, bacterial and fungal infections, chronic ulcers, and verrucous hyperplasia have been reported.' The diabetic patient has additional hazards: there is an increased susceptibility to infection, and below knee amputations heal less well than above knee amputations.2
Localised bullous pemphigoid has been reported occurring around the scar of a previous injury to the leg,3 and some cases of bullous pemphigoid have been observed to start with a localised group of blisters before the generalised eruption.4 There is no increased incidence of bullous pemphigoid in diabetes, however, and there have been no previous reports of the eruption confined to the skin of the amputated stump. The aetiological relevance of trauma is difficult to assess, but blistering due to trauma alone results in skin separation in the granular zone of the epidermis without positive immunofluorescence findings.6
We thank Dr Asthma associated with N-acetylcysteine infusion and paracetamol poisoning: report of two cases
Intravenous infusion of N-acetylcysteine has been shown to be effective and safe for paracetamol poisoning. Side effects are said to be few and serious complications rare.' -3 We, however, describe two patients with a history of asthma in whom an asthmatic reaction occurred after treatment.
Case reports
Case 1-An 18 year old woman was admitted to the emergency centre after having swallowed over the previous seven hours 65 tablets of Di-gesic containing a total of 21 g paracetamol and 2-1 g propoxyphene. She had a history of frequent "bronchitic" cough and hay fever and had been taking antihistamines by mouth and beclomethasone and cromoglycate by inhalation. Physical examination elicited only general weakness and tiredness. N-Acetylcysteine is now available for intravenous use. The indications and methods of administration have been described' and are adopted in this hospital. Prescott and colleagues recommended immediate treatment for any patient presenting within eight hours of ingesting more than 7-5 g paracetamol and that it should be continued or terminated as guided by the serum paracetamol concentration subsequently available. Side effects are said to be few and uncommon and include nausea, vomiting, hypokalaemia, metabolic acidosis, and mild thrombocytopenia. Rarely have these required withdrawal of treatment. Breen et al reported one case of rash necessitating withdrawal.3 Walton and colleagues reported one patient who developed an anaphylactoid reaction with rash, hypotension, and bronchospasm.5 No case of isolated bronchospasm has been reported.
Our two patients were asthmatics who developed bronchospasm after infusion of a loading dose of N-acetylcysteine. Arguably the asthmatic attack might have resulted from paracetamol ingestion or from the emotional stress that precipitated or accompanied admission to hospital, but we think that the timing of the onset of symptoms in relation to the infusion makes the latter highly suspect. Asthma has not been reported after paracetamol poisoning. The temporal sequence of events strongly suggests that the intravenous infusion of Nacetylcysteine precipitated the attack in these two patients. Alternatively, an interaction between paracetamol and N-acetylcysteine might have led to bronchospasm. The underlying mechanism is unexplained. Though bronchospasm is well recognised to occur after local bronchial instillation of N-acetylcysteine by inhalation (Mucomyst), such reaction is considered to be a local irritant rather than systemic effect.
We conclude that the possibility of inducing severe bronchospasm should be borne in mind when using N-acetylcysteine to treat paracetamol poisoning in asthmatic subjects. Should more similar side effects be reported with this treatment, the recommendation of administering N-acetylcysteine before the serum paracetamol concentration is known may need reconsideration. 
Subjects, methods, and results
The study was conducted in schoolchildren from the Lilongwe District, Malawi. One population (school 1) comprised 57 subjects (37 boys, 20 girls; are range 6-14 years, mean 9 2) infected with S mansoni, and the other population (school 2) comprised 66 subjects (56 boys, 10 girls; age range 9-20 years, mean 14-0), 60 of whom were infected with concomitant S mansoni and S haematobium, four with S mansoni, and two with S haematobium.
S mansoni infection was assessed by determining the faecal egg load on at least two separate occasions using a thick smear technique.2 S haematobium was assessed on midday urine samples using a filtration technique.3
Post-treatment assessments were made on single specimens obtained at one and three months (and at six months at school 2).
Subjects from school 1 were allocated to two nominal dosage schedules of oxamniquine plus praziquantel on the basis of egg counts: 4 0+8 0 mg/kg, and 7-5+ 10-0 mg/kg. The mixed infection population (school 2) was similarly allocated to doses of oxamniquine and praziquantel: 7-5+15-0 mg/kg, and 10-0+20-0 mg/kg.
Egg counts were expressed as group mean values using square root transformation. Efficacy was expressed as percentage reduction in mean egg count for each treatment group. The two infections were assessed separately, so that subjects harbouring both parasites were used for the assessment of efficacy against each.
Pretreatment S mansoni egg loads in the population (school 1) infected with this parasite only were higher than in the other population carrying concomitant S haematobium (see Side effects occurred in four subjects (3%). Two reported abdominal pain and headache, one noted a rash 24 hours after treatment, and one with mixed infection reported dizziness eight hours after treatment.
Comment
These results show the high efficacy of simultaneous oxamniquine and praziquantel in low single doses of 7-5 and 15-0 mg/kg, respectively, against S mansoni and S haematobium. These doses are considerably lower than those used in Malawi for each drug administered alone-oxamniquine 30 mg/kg (Teesdale, Chitsulo, and Pugh, unpublished data), praziquantel 40 mg/kg.4
The combined treatment was well tolerated, side effects being of low incidence and self limiting. Our impression is that a higher incidence and a greater severity of side effects are found in these areas with very heavy S mansoni infections after treatment with either oxamniquine or praziquantel administered alone.
Low dose coadministration could confer a cost advantage with the potential benefit of an increase in tolerance without loss of efficacy. There would be further grounds for continued interest if resistance to a single schistosomicide ever became established. While it might be argued that low dosage could result in the emergence of resistance, this issue has usually been raised in connection with suppressive treatment. The question of resistance cannot be excluded in view of the increasing popularity of population based chemotherapy programmes. 5 Our results have been confirmed by a Zambian study, in which the additional assessment of labQratory safety parameters was satisfactory (Njelesani and Ekue, unpublished data). Further studies are planned in Sudan, Kenya, and Zimbabwe to confirm efficacy and tolerance of oxamniquine and praziquantel 7-5 + 15-0 mg/kg.
